They way I understand it is the phase three trial is newly acquired GBM not recurrent. There is a difference. I believe that is the reason KITE achieved approval from a phase 2 rather than having to do a phase 3 trial.
On the blood cancers, I do not know the numbers but many/most patients relapse while still in good health. So the second and third line markets can be quite large.
In GBM, nothing really works well second line. So the money is first line (including adjuvant).
[I guess the Hat and Avaston have been shown to "work" if one counts such minor benefit]
DCVax, assuming the trial top line numbers confirm what is widely believed here, would clearly become, together with surgery and chemo, the SOC for GBM, or at least for the patients with best response, though I think it would be used for all patients unless indications are that it is counter productive or not helpful for certain sub-groups. But I definitely don’t see it as second line.
Market Data 
Markets 
AI
